Development and Validation of Adaptable Skin Cancer Classification System Using Dynamically Expandable Representation
10.4258/hir.2024.30.2.140
- Author:
Bong Kyung JANG
1
;
Yu Rang PARK
Author Information
1. Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea
- Publication Type:Original Article
- From:Healthcare Informatics Research
2024;30(2):140-146
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:Skin cancer is a prevalent type of malignancy, necessitating efficient diagnostic tools. This study aimed to develop an automated skin lesion classification model using the dynamically expandable representation (DER) incremental learning algorithm. This algorithm adapts to new data and expands its classification capabilities, with the goal of creating a scalable and efficient system for diagnosing skin cancer.
Methods:The DER model with incremental learning was applied to the HAM10000 and ISIC 2019 datasets. Validation involved two steps: initially, training and evaluating the HAM10000 dataset against a fixed ResNet-50; subsequently, performing external validation of the trained model using the ISIC 2019 dataset. The model’s performance was assessed using precision, recall, the F1-score, and area under the precision-recall curve.
Results:The developed skin lesion classification model demonstrated high accuracy and reliability across various types of skin lesions, achieving a weighted-average precision, recall, and F1-score of 0.918, 0.808, and 0.847, respectively. The model’s discrimination performance was reflected in an average area under the curve (AUC) value of 0.943. Further external validation with the ISIC 2019 dataset confirmed the model’s effectiveness, as shown by an AUC of 0.911.
Conclusions:This study presents an optimized skin lesion classification model based on the DER algorithm, which shows high performance in disease classification with the potential to expand its classification range. The model demonstrated robust results in external validation, indicating its adaptability to new disease classes.
